2025-10-11 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the data you provided, presented in English with numerical summaries and concise analysis.

## JNJ Stock Analysis

**Company Overview:** Johnson & Johnson (JNJ) is a global healthcare company engaged in the research, development, manufacture, and sale of a broad range of products in the healthcare field.

### 1.  Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 46.55%
*   **VOO Cumulative Return:** 99.08%
*   **Absolute Deviation:** -53.5%
*   **Relative Deviation:** 14.6 (Indicates the current deviation is at the 14.6th percentile of its historical range.)

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period considered. The relative deviation suggests that this underperformance is near the lower end of its historical range compared to the S&P 500.

**Alpha, Beta Analysis Table:**

| Year       | CAGR    | MDD     | Alpha  | Beta  | Cap(B) |
| ---------- | ------- | ------- | ------ | ----- | ------ |
| 2015-2017  | 26.0%   | 66.8%   | -2.0%  | -0.1  | 336.5  |
| 2016-2018  | 14.0%   | 10.7%   | -1.0%  | 0.1   | 310.8  |
| 2017-2019  | 20.0%   | 71.5%   | -2.0%  | 0.4   | 351.3  |
| 2018-2020  | 19.0%   | 79.2%   | -4.0%  | 0.4   | 379.1  |
| 2019-2021  | 33.0%   | 79.2%   | -14.0% | 0.5   | 412.0  |
| 2020-2022  | 8.0%    | 79.6%   | 9.0%   | 0.4   | 425.5  |
| 2021-2023  | -19.0%  | 79.6%   | -20.0% | 0.3   | 377.5  |
| 2022-2024  | -32.0%  | 79.6%   | -53.0% | 0.3   | 348.3  |
| 2023-2025  | 18.0%   | 79.6%   | -46.0% | 0.1   | 458.4  |

**Analysis:**
*   **CAGR:** The Compound Annual Growth Rate varies significantly across the years, showing periods of strong growth and significant declines.
*   **MDD:**  The Maximum Drawdown is consistently high, indicating substantial risk in holding JNJ over these periods.
*   **Alpha:**  Alpha is generally negative, suggesting JNJ has underperformed its benchmark on a risk-adjusted basis, except for the 2020-2022 period.
*   **Beta:**  Beta values are mostly positive but low, indicating JNJ's price is not strongly correlated with the overall market.
*   **Cap(B):** Market Capitalization has varied.

### 2. Recent Stock Price Movement

*   **Current Price:** 190.315
*   **Last Market Data:** Price: 190.32, Previous Close: 191.08, Change: -0.4
*   **5-day Moving Average:** 189.139
*   **20-day Moving Average:** 181.5013
*   **60-day Moving Average:** 175.9361

**Analysis:** The current price is slightly below the previous close, indicating a minor dip.  The 5-day moving average is above the 20-day and 60-day moving averages, and the 20-day moving average is above the 60-day moving average suggesting a short-term upward trend.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 86.81 (Overbought)
*   **PPO:** 0.4792
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (5 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Recent (20-day) Relative Deviation Change:** +1.8 (Short-term Increase)
*   **Expected Return:** -120.4% (vs. S&P 500, Long-term)
*   **Last Market Data Change:** Price: 190.32, Previous Close: 191.08, Change: -0.4 (slight decrease)

**Analysis:**

*   **MRI:**  Indicates a high investment recommendation, suggesting the model assesses JNJ as relatively safe.
*   **RSI:** The high RSI value indicates that the stock is overbought and might be due for a correction.
*   **PPO:** The Positive value of PPO indicates that the short-term moving average is above the long-term moving average, suggesting an upward trend.
*   **Hybrid Signal:** The hybrid signal recommends buying, but the recommendation is tempered by the high MRI, and is conservative.
*   **Relative Deviation Change:** A positive change in relative deviation suggests recent improvement in performance compared to the benchmark.
*   **Expected Return:**  The significantly negative expected return suggests potential underperformance relative to the S&P 500 over the long term, despite the MRI suggesting safety.
*   **Last Market Data Change:** The slight decrease in price might suggest a minor correction or consolidation after a recent upward move.

### 4. News and Analyst Opinions

*   **Recent News:** Includes headlines about sector decline, potential acquisitions (Protagonist Therapeutics), and discussions around Q3 earnings expectations. The Trump tariff news could induce market volatility across the board.
*   **Analyst Consensus:**
    *   Rating: ~Buy (2.12)
    *   Target Price: 187.49 (Average), 213.00 (High), 155.00 (Low)

**Analysis:** Recent news presents a mixed picture. Acquisition talks can be positive, while sector-specific headwinds and broader market concerns (tariffs) are negative. Analyst consensus leans toward a "Buy" rating, but the average target price is slightly *below* the current price, suggesting limited upside potential according to analysts.

### 5. & 6. Earnings & Financial Information

**Recent Earnings:**

| 날짜       | EPS   | 매출        |
| ---------- | ----- | ----------- |
| 2025-07-24 | 2.3   | 23.74 B$    |
| 2025-04-23 | 4.57  | 21.89 B$    |
| 2024-10-23 | 1.12  | 22.47 B$    |
| 2024-07-25 | 1.95  | 22.45 B$    |
| 2025-07-24 | 1.95  | 22.45 B$    |

**Analysis:** The EPS and revenue figures show fluctuations. The EPS in the most recent quarter is lower than the previous one, but Revenue has increased.

**Financial Information Tables:**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
| ------------ | ----------- | ------------- |
| 2025-06-30   | $23.74B     | 67.87%        |
| 2025-03-31   | $21.89B     | 66.40%        |
| 2024-12-31   | $22.52B     | 68.35%        |
| 2024-09-30   | $22.47B     | 69.01%        |
| 2024-06-30   | $22.45B     | 69.40%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE     |
| ------------ | ----------- | ------- |
| 2025-06-30   | $78.47B     | 7.06%   |
| 2025-03-31   | $78.11B     | 14.08%  |
| 2024-12-31   | $71.49B     | 4.80%   |
| 2024-09-30   | $70.16B     | 3.84%   |
| 2024-06-30   | $71.54B     | 6.55%   |

**Analysis:**

*   **Revenue:** Revenue has generally been increasing, indicating top-line growth.
*   **Profit Margin:** Profit margins are consistently high, suggesting strong operational efficiency.
*   **Equity:** Equity has been increasing, reflecting overall financial health.
*   **ROE:** ROE varies, with a recent decrease, indicating fluctuations in the return on shareholders' equity.

### 7. Overall Summary

JNJ exhibits a mixed picture. While it displays strong financial health with increasing revenue, high profit margins, and increasing equity, it has significantly underperformed the S&P 500. Technical indicators suggest it's currently overbought, and analysts' target prices indicate limited upside. The recent news flow includes potential positives (acquisitions) and negatives (sector headwinds, tariffs).  The MRI suggests a relatively safe investment, but the significantly negative expected return compared to the S&P 500 is concerning. The recommendation buy from the hybrid signal has to be evaluated carefully because of the RSI values. The company's financials and dividends might make it appealing as a long-term defensive holding, but potential investors should be aware of the underperformance relative to the broader market.
